Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Effect of Treatment With Colchicine After Acute Coronary Syndrome on Major Cardiovascular Events: A Systematic Review and Meta-Analysis of Clinical Trials Publisher Pubmed



Razavi E1 ; Ramezani A1 ; Kazemi A2 ; Attar A3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Nutrition Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  3. 3. Department of Cardiovascular Medicine, TAHA Clinical Trial Group, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Source: Cardiovascular Therapeutics Published:2022


Abstract

Aim. Colchicine as an anti-inflammatory drug might be effective in the treatment of atherosclerosis, an inflammatory-based condition. The aim of this systematic review and meta-analysis was to evaluate the impact of colchicine on acute coronary syndrome (ACS). Methods. We searched SCOPUS, PubMed, and Web of Science up to September 27, 2020. All clinical trials which evaluated the effect of colchicine on ACS patients and reported high-sensitivity C-reactive protein (hs-CRP) serum level or gastrointestinal (GI) adverse events with at least 5-day follow-up or death, myocardial infarction (MI), and stroke with at least 30-day follow-up as outcomes were included. Results. Finally, seven publications were analyzed. The results of our study revealed that colchicine has a marginally significant effect on hs-CRP attenuation. Furthermore, colchicine manifested promising results by declining the risk of stroke by 70%. However, MI and primary composite endpoint did not differ between the colchicine and noncolchicine groups. Although colchicine did not significantly increase GI adverse events in the pooled analysis, the dose-dependent effect was detected. Low-dose consumption can avoid GI side effects of colchicine. Conclusion. Colchicine has shown some molecular and clinical promising results in ACS patients. The lack of effect of colchicine on MI and all-cause mortality can be partly attributed to the limitations of previous studies. Since colchicine is an inexpensive and easy-to-access drug that has shown to be safe in low-dose regimens in the clinical setting; it would be worthy that future large-scale well-designed clinical trials address this issue by resolving the limitations of previous investigations. © 2022 Erfan Razavi et al.
Related Docs
1. Preprocedural Colchicine in Patients With Acute St-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: A Randomized Controlled Trial (Podcast-Pci), Journal of Cardiovascular Pharmacology (2022)
2. Functions and Therapeutic Interventions of Non-Coding Rnas Associated With Tlr Signaling Pathway in Atherosclerosis, Cellular Signalling (2022)
3. Electrochemical-Based Biosensors: New Diagnosis Platforms for Cardiovascular Disease, Current Medicinal Chemistry (2020)
4. The Role of Mesenchymal Stem Cells in Atherosclerosis: Prospects for Therapy Via the Modulation of Inflammatory Milieu, Journal of Clinical Medicine (2019)
5. Exosomal Non-Coding Rnas: Emerging Therapeutic Targets in Atherosclerosis, Biochemical Pharmacology (2023)
6. Pcsk9 Pathway-Noncoding Rnas Crosstalk: Emerging Opportunities for Novel Therapeutic Approaches in Inflammatory Atherosclerosis, International Immunopharmacology (2022)
7. Nlrp3 Inflammasome Pathway in Atherosclerosis: Focusing on the Therapeutic Potential of Non-Coding Rnas, Pathology Research and Practice (2023)
8. The Relationship Between Serum Levels of Hs-Crp and Coronary Lesion Severity, Clujul Medical (2016)
Experts (# of related papers)
View all Related Experts
Mohammad Alidoosti (1)
Masoud Eslami (1)